Cargando…
Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
The frequent activation of the PI3K/AKT/mTOR pathway and its crucial role in estrogen receptor-positive (ER+) breast cancer tumorigenesis and drug resistance has made it a highly attractive therapeutic target in this breast cancer subtype. Consequently, the number of new inhibitors in clinical devel...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003259/ https://www.ncbi.nlm.nih.gov/pubmed/36901954 http://dx.doi.org/10.3390/ijms24054522 |